Sarepta’s stock plunges after Duchenne gene therapy fails to meet main goal in key trial

The Cambridge biotech said late Monday that its gene therapy to treat Duchenne muscular dystrophy failed to meet the primary goal of a large Phase 3 trial, but that it plans to seek full approval regardless.